

New Hampshire Medicaid Fee-for-Service Program

Oral NSAIDs and Combinations Legend (Rx Required) Criteria

Approval Date: December 3, 2019

Medications

Brand Names	Generic Names	Dosage	Indications
Cambia [®]	diclofenac potassium	50 mg, powder for oral solution	Acute treatment of migraine attacks with or without aura in adults (≥18 years old)
Zipsor [®]	diclofenac potassium	25 mg	Relief of mild to moderate acute pain.
Zorvolex [®]	diclofenac potassium	18 mg, 35 mg	Relief of mild to moderate acute pain
Vimovo [®]	esomeprazole/ naproxen	20 mg/375 mg, 20 mg/500 mg	Relief of signs and symptoms of osteoarthritis, RA and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers
Duexis [®]	ibuprofen/famotidine	800 mg/26.6 mg	Relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis and to decrease the risk of developing upper GI ulcers
Celebrex [®]	celecoxib	100 mg, 200 mg, 400 mg	Indicated for relief of the signs and symptoms of ankylosing spondylitis in adults, juvenile rheumatoid arthritis (JRA) in patients 2 years and older, osteoarthritis in adults, acute pain in adults, primary dysmenorrhea in adults, and rheumatoid arthritis in adults
Mobic [®]	meloxicam	7.5 mg, 15 mg	indicated for relief of the symptoms of pauciarticular and/or polyarticular course juvenile rheumatoid arthritis in children 2 years or older, osteoarthritis in adults, and rheumatoid arthritis in adults. The oral tablets and orally-disintegrating tablets are only indicated for children weighing at least 60 kg.
Qmiiz ODT [™]	meloxicam	7.5 mg, 15 mg	indicated for relief of the symptoms of pauciarticular and/or polyarticular course juvenile rheumatoid arthritis in children 2 years or older, osteoarthritis in adults, and rheumatoid arthritis in adults. The oral tablets and orally-disintegrating tablets are only indicated for children weighing at least 60 kg.
Vivlodex [™]	meloxicam	5 mg, 10 mg	indicated for relief of the symptoms of pauciarticular and/or polyarticular course juvenile rheumatoid arthritis in children 2 years or older, osteoarthritis in adults, and rheumatoid arthritis in adults. The oral tablets and orally-disintegrating tablets are only indicated for children weighing at least 60 kg.

Proprietary & Confidential

© 2003–2019 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

Cambia[®], Zipsor[®], and Zorvolex[®]

Criteria for Approval

1. Patient is ≥ 18 years old; **AND**
2. Electronic look back of 100 days for oral generic diclofenac product; **AND**
3. Electronic look back of 100 days for oral generic NSAID product.

Criteria for Denial

1. Criteria for approval not met.
2. History of gastrointestinal contraindications to oral NSAIDs.
3. Cambia[®] only: for diagnosis of prophylactic therapy of migraine or cluster headache.

Length of Approval: One year

Combination Products

Criteria for Approval

1. Patient is ≥ 18 years old; **AND**
2. Electronic look back of 100 days for each single product ingredient.

Criteria for Denial

1. Criteria for approval not met.
2. History of gastrointestinal contraindications to oral NSAIDs.

Length of Approval: One year

Celebrex[®], Mobic[®], Qmiiz ODT[™], Vivlodex[™]

Criteria for Approval

1. Patient is of FDA-approved age for medication requested; **OR**
2. Patient has failed or is intolerant to two or more non-selective NSAIDs, one of which must be etodolac, disulfiram, diclofenac, or piroxicam; **AND**
3. Non-preferred drugs on the Preferred Drug List (PDL) require failure on preferred drugs first.

Criteria for Denial

1. Prior approval will be denied if the approval criteria are not met.
2. Contraindication to Celebrex®: Sulfonamide allergy.
3. Perioperative period for coronary artery bypass graft (CABG) surgery.
4. Concomitant use of warfarin or another NSAID.

Length of Approval: One year

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	03/22/2010
Commissioner	Approval	04/30/2010
DUR Board	Revision	06/18/2012
Commissioner	Approval	07/10/2012
	New Drug to Market	09/02/2014
DUR Board	Revision	03/20/2017
Commissioner	Approval	06/08/2017
DUR Board	Revision	03/12/2019
Commissioner Designee	Approval	04/05/2019
DUR Board	Update	10/28/2019
Commissioner Designee	Approval	12/03/2019